ReviewCold Spring Harbor perspectives in medicine2016
Fusidic Acid: A Bacterial Elongation Factor Inhibitor for the Oral Treatment of Acute and Chronic Staphylococcal Infections.
Review in Cold Spring Harbor perspectives in medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 141 citations in OpenAlex.
- Staphylococcus aureus biofilms: molecular mechanisms, resistance determinants, and emerging therapeutic strategies.Molecular biology reports · 2026Review
- Elongation Factor-G (Antibiotics (Basel, Switzerland) · 2026Article
- Of Commensals and Opportunists: Genomics of Coagulase-Negative Staphylococci During Sequential Ear and Eye Infections in a Healthy Adult.MicrobiologyOpen · 2026Article
- Bacteriophage and Fusidic Acid Have Synergistic Effect Against Meticillin-Resistant Staphylococcus pseudintermedius in Ex Vivo Canine Dermis Model.Veterinary dermatology · 2026Article
- Iron(III)-Tropolone Complex as a Topical Agent Against Drug-Resistant MRSA Skin Infections.Antibiotics (Basel, Switzerland) · 2026Article
- Identification of bacterial key genes and therapeutic targets in hypertensive patients with type 2 diabetes through bioinformatics analysis.Scientific reports · 2026Article
- First Report ofMicroorganisms · 2026Article
- Isolation and identification of antibiotic-resistant bacteria in hospital tap water.Frontiers in antibiotics · 2026Article
- Olefinic side chain modification of fusidic acid enhances anti-MRSA activity and mitigates resistance development.RSC medicinal chemistry · 2025Article
- Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Emericellopsic acid, a helvolic acid derivative with a 6/5/7/5 tetracyclic skeleton from sponge-derived Emericellopsis maritima.The Journal of antibiotics · 2025Article
- Genomic characterisation of nasal isolates of coagulase-negative Staphylococci from healthy medical students reveals novel Staphylococcal cassette chromosome mec elements.Scientific reports · 2025Article
- Multi-Modal Design, Synthesis, and Biological Evaluation of Novel Fusidic Acid Derivatives.Molecules (Basel, Switzerland) · 2025Article
- Metabolic engineering approaches for the biosynthesis of antibiotics.Microbial cell factories · 2025Review
- Exploration of the Fusidic Acid Structure Activity Space for Antibiotic Activity.Molecules (Basel, Switzerland) · 2025Article
- House dust-a Pandora's box of antimicrobial resistance (AMR) activity?Sustainable microbiology · 2025Article
- SVC112: From Hummingbirds to Head and Neck Cancer.Advances in experimental medicine and biology · 2025Article
- Transcriptomic and metabolomic insights into the antimicrobial mechanisms ofFrontiers in plant science · 2025Article
- A novel methionyl-tRNA synthetase inhibitor targeting gram-positive bacterial pathogens.Antimicrobial agents and chemotherapy · 2024Article
- Antimicrobials in Orthopedic Infections: Overview of Clinical Perspective and Microbial Resistance.Medicina (Kaunas, Lithuania) · 2024Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fusidic acid is an oral antistaphylococcal antibiotic that has been used in Europe for more than 40 years to treat skin infections as well as chronic bone and joint infections. It is a steroidal antibiotic and the only marketed member of the fusidane class. Fusidic acid inhibits protein synthesis by binding EF-G-GDP, which results in the inhibition of both peptide translocation and ribosome disassembly. It has a novel structure and novel mode of action and, therefore, there is little cross-resistance with other known antibiotics. Many mutations can occur in the FusA gene that codes for EF-G, and some of these mutations can result in high-level resistance (minimum inhibitory concentration [MIC] > 64 mg/L), whereas others result in biologically unfit staphylococci that require compensatory mutations to survive. Low-level resistance (<8 mg/L) is more common and is mediated by fusB, fusC, and fusD genes that code for small proteins that protect EF-G-GDP from binding fusidic acid. The genes for these proteins are spread by plasmids and can be selected mostly by topical antibiotic use. Reports of resistance have led to combination use of fusidic acid with rifampin, which is superseded by the development of a new dosing regimen for fusidic acid that can be used in monotherapy. It consists of a front-loading dose to decrease the potential for resistance development followed by a maintenance dose. This dosing regimen is now being used in clinical trials in the United States for skin and refractory bone and joint infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.